SCHEDULE: Dialectic Entities Amend DiaMedica Ownership to 0.3%

Dialectic Life Sciences SPV LLC and related entities filed an amended Schedule 13G, reporting John Fichthorn's beneficial ownership of 0.3% in DiaMedica Therapeutics Inc.

Summary

• Dialectic Life Sciences SPV LLC, Dialectic LS Manager LLC, Dialectic Capital Management, LP, Dialectic Partners, LLC, and John Fichthorn filed an Amendment No. 1 to Schedule 13G.
• The filing pertains to Voting common shares, no par value per share, of DiaMedica Therapeutics Inc. (CUSIP: 25253X207).
• The event date requiring this filing was December 31, 2025.
• John Fichthorn beneficially owns 153,983 shares, representing 0.3% of the class.
• The other Dialectic reporting persons (Dialectic Life Sciences SPV LLC, Dialectic LS Manager LLC, Dialectic Capital Management, LP, and Dialectic Partners, LLC) report 0 shares beneficially owned and 0% of the class.
• John Fichthorn holds sole voting and sole dispositive power over his 153,983 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory filing. It provides transparency on beneficial ownership but offers no new insights into the company's operational or financial performance.

Positives

• The filing indicates a passive investment stance, with no intent to change or influence control of DiaMedica Therapeutics Inc.

Negatives

• No significant negative information is contained within this routine ownership disclosure.

Risks

• This filing does not contain specific risk factors related to DiaMedica Therapeutics Inc. beyond the inherent risks of equity ownership.

Future Outlook

This Schedule 13G Amendment No. 1 is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from DiaMedica Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors holding less than 20% of a company's shares. This filing reflects a minor adjustment or confirmation of a passive stake by Dialectic entities and John Fichthorn in DiaMedica Therapeutics Inc., which is common in the investment landscape and does not inherently signal a shift in broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides updated information on a passive beneficial ownership stake, which is unlikely to have a material impact on the company's strategic direction or share price given the low percentage.

Key Dates

Keywords

DiaMedica Therapeutics Inc., Schedule 13G, Beneficial Ownership, John Fichthorn, Dialectic Life Sciences SPV LLC, Passive Investment, Equity Ownership, SEC Filing